Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis

European Journal of Dermatology

Volumn 25, Issue 4, 2015, Pages 344-

  Du Thanh, AurÉlie ^a   Pallure, ValÉrie ^a   Girard, CÉline ^a   Dereure, Olivier ^a   Guillot, Bernard ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; IPILIMUMAB; METRONIDAZOLE; PRISTINAMYCIN; STEROID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; AGED; BLOOD ANALYSIS; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CYTOLOGY; DIARRHEA; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; LETTER; NEUTROPHIL; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTION; COMPLICATION; PEPTOCLOSTRIDIUM DIFFICILE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DIARRHEA; FEMALE; HUMANS;

EID: 84941799804     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2015.2561     Document Type: Letter

References (9)

1. Jarvis WR, Schlosser J, Jarvis AA, et al. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009; 37: 263-70.
2. Ozaki E, Kato H, Kita H, et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol 2004; 53: 167-72.
3. Whitehead SJ, Shipman KE, Cooper M, et al. Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples? J Med Microbiol 2014; 63: 590-3.
4. Khan A, Raza S, Batul SA, et al. The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat Antiinfect Drug Discov 2012; 7: 157-70.
5. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-98.
6. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
7. Kahler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277-86.
8. Hold GL, Smith M, Grange C, et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years? World J Gastroenterol 2014; 20: 1192-210.
9. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-12.